Skip to main content
Premium Trial:

Request an Annual Quote

Six New RNAi-Related Patent Applications Published By US Patent Office: May 14, 2004

Premium

Title: Antisense Compounds, Methods, and Compositions for Treating MMP-12-Related Inflammatory Disorders. Number: 20040087533. Filed: July 16, 2003. Lead Inventor: Andreas Dieckmann, Karolinska Institute.

The patent application, its abstract states, covers “antisense oligonucleotide compounds for use in modulating the function of nucleic acid molecules encoding mammalian MMP-12 (metalloproteinase 12). More specifically, the invention provides compounds of 8 to 50 nucleobases in length capable of specifically hybridizing with nucleic acid molecules encoding MMP-12 and thereby inhibiting the expression of the MMP-12 protein product, as well as pharmaceutical compositions thereof and methods of its use,” the abstract adds.

The application specifically claims an RNAi molecule that is used to modulate MMP-12.


Title: Compositions and Methods for the Treatment of Cancer. Number: 20040087531. Filed: May 16, 2003. Lead Inventor: Adam Telerman, Molecular Engines Laboratories.

The patent application’s abstract states that the invention comprises “composition[s] and methods of treating, preventing, and managing cancer by inhibiting the expression of the gene tpt1.”

The application claims “a method of suppressing growth of a cancer cell comprising contacting the cell with a compound that inhibits the synthesis or expression of tpt1 in an amount sufficient to cause such inhibition.” This compound, which is complementary to “at least part of tpt1 mRNA,” can be “a tpt1 siRNA,” the application states.


Title: Compositions and Methods for Cell Dedifferentiation and Tissue Regeneration. Number: 20040087016. Filed: May 16, 2003. Lead Inventor: Mark Keating, University of Utah.

According to the patent application’s abstract, the invention “provides methods and compositions to dedifferentiate a cell. The ability of the methods and compositions … to promote the dedifferentiation of differentiated cells, including terminally differentiated cells, can be used to promote regeneration of tissue and organs in vivo,” the abstract notes.

This ability “can further be used to produce populations of stem or progenitor cells, which can be used to promote regeneration of tissues and/or organs damaged by injury or diseases,” the abstract adds. “Accordingly, the present invention provides novel methods for the treatment of a wide range of injuries and diseases that affect many diverse cell types.”

The patent application claims a method of dedifferentiating a differentiated mammalian cell using an RNAi construct.


Title: Inhibition of Gene Expression in Vertebrates Using Double-Stranded RNA (RNAi). Number: 20040086911. Filed: June 24, 2003. Lead Inventor: Olga Cabello, Baylor College of Medicine.

The patent application, states its abstract, covers “RNA interference using novel compositions and methods. In particular embodiments, the RNA compositions comprise double strand regions interrupted with non-complementary regions, wherein the RNA compositions are effective for regulation of transcription,” the abstract states.

“In specific embodiments, transcription of a target nucleic acid sequence to which the RNA composition is directed is reduced or inhibited, such as by inducing destruction of at least one transcript,” the abstract adds. “In other embodiments, multiple target nucleic acid sequences are targeted by the RNA compositions of the present invention.”


Title: Methods and Compositions for RNA Interference. Number: 20040086884. Filed: Jan. 24, 2003. Lead Inventor: David Beach, Genetica (Cold Spring Harbor Laboratory).

“The present invention,” the patent application’s abstract states, “provides methods for attenuating gene expression in a cell using gene-targeted double-stranded RNA. The dsRNA contains a nucleotide sequence that hybridizes under physiologic conditions of the cell to the nucleotide sequence of at least a portion of the gene to be inhibited.”


Title: Methods of Producing RNAs of Defined Length and Sequence. Number: 20040086860. Filed: Oct. 4, 2002. Lead Inventor: Muhammad Sohail, University of Oxford.

The patent application’s abstract states that the invention comprises “methods of making RNA duplexes and single-stranded RNAs of a desired length and sequence based on cleavage of RNA molecules at a defined position, most preferably with the use of deoxyribozymes.”

The abstract adds that “novel deoxyribozymes, capable of cleaving RNAs including a leader sequence at a site 3’ to the leader sequence, are also described.”

 

The Scan

Billions for Antivirals

The US is putting $3.2 billion toward a program to develop antivirals to treat COVID-19 in its early stages, the Wall Street Journal reports.

NFT of the Web

Tim Berners-Lee, who developed the World Wide Web, is auctioning its original source code as a non-fungible token, Reuters reports.

23andMe on the Nasdaq

23andMe's shares rose more than 20 percent following its merger with a special purpose acquisition company, as GenomeWeb has reported.

Science Papers Present GWAS of Brain Structure, System for Controlled Gene Transfer

In Science this week: genome-wide association study ties variants to white matter stricture in the brain, and more.